5th April 2011: Trojantec Ltd. announced today that two studies were presented at the 102nd Annual Meeting of AAACR held at Orlando, Florida, April 2-6th 2011.

STUDY 1 Intracellular Delivery of Therapeutic siRNA via an antennapedia -RNA-binding fusion peptide.
The Potential of RNAi

RNA silencing ( siRNA) is a biological process that can silence genes and thereby block the production of disease-causing proteins before they are made.

siRNA has the potential to become an entirely new class of human therapeutics that could treat many human diseases including cancer.

siRNA Delivery Problem

However, when siRNA is given on its own it cannot enter cells .Thus it requires an additional delivery technology in order to enter cells and produce its intended effect. This ability to deliver siRNA into the cell is critical to the success of the technology. siRNA delivery technologies are, perhaps, as important to the safety and efficacy of the siRNA therapeutic as the siRNA warhead itself.

Solving the RNAi Delivery Problem

Trojantec presented at AACR 2011 on Tuesday April 5,2011 first data on its technology which may solve this problem. The work was conducted at the University of Westminster under the supervision of Dr Angray Kang. Dr Kang said' Although this is preliminary work ,Trojantec's siRNA delivery technology has the potential to target all cells in a non-cytotoxic way and may allow internalization of both the transporter and the cargo, which on this occasion is siRNA.

STUDY 2 TR4 for the treatment of human neoplasms: Novel antiNotch agent.

A novel Notch Inhibitor

This study continues on the work previously presented at ASCO 2009 and it expands on the published study reported on TR4 ,a Notch inhibitor. TR4 is a therapeutic protein blocking the Notch pathway which is a critical pathway for some Cancer Stem Cells. TR4 was effective , leading to Cancer Cell death in tumors that had increased Notch activity. It was found that TR4 could inhibit human breast and colon tumors grown in immuno-deficient mice.

The current study was conducted by a scientists in the Biochemistry Department of Imperial College London, lead by Dr Mahendra Deonarain . Dr Deonarain said ‘The study confirmed the ability of TR4 to act as a pure Notch inhibitor acting at the nuclear level and achieving selective inhibition of human breast cancer cells transplanted onto immunodeficient mice. This paves the way for clinical development'.